Andreas Hollenstein
Senior Principal Scientist - Immunosafety Roche
Andreas holds an MS in Biochemistry/Molecular Biology and completed his PhD at ETH Zürich in the field of Radio-Oncology. After postdoctoral research in adoptive cell therapy at the Dutch Cancer Institute in the lab of Ton Schumacher, he focused on antibody discovery and lead optimization at Genmab NL. Andreas joined Roche in Basel in 2020 as a scientist in immunosafety, where he focuses on the development of safer and less immunogenic therapeutics.
Seminars
With bispecifics and T-cell engagers advancing rapidly, early-stage development carries significant translational, immunogenicity, and safety risk. This workshop will explore how to design integrated preclinical packages that better predict human pharmacology, safety, and immune-related liabilities, enabling more confident progression into the clinic. Participants will learn how to align mechanism-of-action, safety, and immunogenicity assessments to build confidence in human outcomes and accelerate early clinical decision-making.
This workshop will gather experts to discuss:
- Optimise biologics for safety, efficacy and immunogenicity to confidently de-risk bispecifics and TCEs before entering clinical studies
- Identify and mitigate immune-related and safety liabilities early, strengthening predictivity and reducing clinical development risk
- Leverage mechanism-of-action insights to integrate safety and immunogenicity considerations into preclinical packages to accelerate regulatory approval and clinic readiness
- Which preclinical models have proven most predictive for bispecifics, TCEs, and ADCs- including safety and immunogenicity risk, and which consistently fail to translate?
- How do teams combine in vitro, in vivo, and computational approaches to reduce uncertainty before first-in-human studies?
- What translational signals provide sufficient confidence to advance a program, and how do teams actively manage remaining risk?
